91制片厂

Published on Market Research Reports庐 Inc. ()

Home > Global Non-beta-lactam Antibiotics Market Growth (Status and Outlook) 2024-2030

Global Non-beta-lactam Antibiotics Market Growth (Status and Outlook) 2024-2030

Publication ID: 
LPI07243974
Publication Date: 
July 16, 2024
Pages: 
86
Publisher: 
LPI
Countries: 
Global [1]
USD 3,660.00

Please choose the suitable license type from above. More details are given under tab "Report License Types" below.

Pharmaceutical Manufacturing [2]
Healthcare [3]
Pharma & Healthcare [4]
Description: 

Non-beta-lactam antibiotics are a broad class of antimicrobial agents that do not contain the beta-lactam ring structure found in penicillins, cephalosporins, and other similar antibiotics. These drugs are crucial in treating bacterial infections, particularly those caused by bacteria resistant to beta-lactam antibiotics. Non-beta-lactam antibiotics encompass various types, including macrolides, fluoroquinolones, tetracyclines, and aminoglycosides, each working through different mechanisms to inhibit bacterial growth or kill bacteria. Their diverse modes of action and range of target bacteria make them essential tools in combating a wide array of infectious diseases.
The global Non-beta-lactam Antibiotics market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.
The 鈥淣on-beta-lactam Antibiotics Industry Forecast鈥� looks at past sales and reviews total world Non-beta-lactam Antibiotics sales in 2022, providing a comprehensive analysis by region and market sector of projected Non-beta-lactam Antibiotics sales for 2023 through 2029. With Non-beta-lactam Antibiotics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Non-beta-lactam Antibiotics industry.
This Insight Report provides a comprehensive analysis of the global Non-beta-lactam Antibiotics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Non-beta-lactam Antibiotics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Non-beta-lactam Antibiotics market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Non-beta-lactam Antibiotics and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Non-beta-lactam Antibiotics.
United States market for Non-beta-lactam Antibiotics is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Non-beta-lactam Antibiotics is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Non-beta-lactam Antibiotics is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Non-beta-lactam Antibiotics players cover Teva, Novartis, Cipla, Pfizer, Fresenius Kabi, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Non-beta-lactam Antibiotics market by product type, application, key players and key regions and countries.
Segmentation by Type:
Aminoglycosides
Tetracyclines
Macrolides
Chloramphenicol
Lincomycin
Others
Segmentation by Application:
Hospital
Clinic
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
Segmentation by Type:
Aminoglycosides
Tetracyclines
Macrolides
Chloramphenicol
Lincomycin
Others
Segmentation by Application:
Hospital
Clinic
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Teva
Novartis
Cipla
Pfizer
Fresenius Kabi
Sun Pharmaceutical
Hikma Pharmaceuticals
Lannett Company
FangYuan Pharmaceutical

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents: 

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Non-beta-lactam Antibiotics Market Size 2019-2030
2.1.2 Non-beta-lactam Antibiotics Market Size CAGR by Region (2019 VS 2023 VS 2030)
2.1.3 World Current & Future Analysis for Non-beta-lactam Antibiotics by Country/Region, 2019, 2023 & 2030
2.2 Non-beta-lactam Antibiotics Segment by Type
2.2.1 Aminoglycosides
2.2.2 Tetracyclines
2.2.3 Macrolides
2.2.4 Chloramphenicol
2.2.5 Lincomycin
2.2.6 Others
2.3 Non-beta-lactam Antibiotics Market Size by Type
2.3.1 Non-beta-lactam Antibiotics Market Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Non-beta-lactam Antibiotics Market Size Market Share by Type (2019-2024)
2.4 Non-beta-lactam Antibiotics Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Other
2.5 Non-beta-lactam Antibiotics Market Size by Application
2.5.1 Non-beta-lactam Antibiotics Market Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Non-beta-lactam Antibiotics Market Size Market Share by Application (2019-2024)
3 Non-beta-lactam Antibiotics Market Size by Player
3.1 Non-beta-lactam Antibiotics Market Size Market Share by Player
3.1.1 Global Non-beta-lactam Antibiotics Revenue by Player (2019-2024)
3.1.2 Global Non-beta-lactam Antibiotics Revenue Market Share by Player (2019-2024)
3.2 Global Non-beta-lactam Antibiotics Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Non-beta-lactam Antibiotics by Region
4.1 Non-beta-lactam Antibiotics Market Size by Region (2019-2024)
4.2 Global Non-beta-lactam Antibiotics Annual Revenue by Country/Region (2019-2024)
4.3 Americas Non-beta-lactam Antibiotics Market Size Growth (2019-2024)
4.4 APAC Non-beta-lactam Antibiotics Market Size Growth (2019-2024)
4.5 Europe Non-beta-lactam Antibiotics Market Size Growth (2019-2024)
4.6 Middle East & Africa Non-beta-lactam Antibiotics Market Size Growth (2019-2024)
5 Americas
5.1 Americas Non-beta-lactam Antibiotics Market Size by Country (2019-2024)
5.2 Americas Non-beta-lactam Antibiotics Market Size by Type (2019-2024)
5.3 Americas Non-beta-lactam Antibiotics Market Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Non-beta-lactam Antibiotics Market Size by Region (2019-2024)
6.2 APAC Non-beta-lactam Antibiotics Market Size by Type (2019-2024)
6.3 APAC Non-beta-lactam Antibiotics Market Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Non-beta-lactam Antibiotics Market Size by Country (2019-2024)
7.2 Europe Non-beta-lactam Antibiotics Market Size by Type (2019-2024)
7.3 Europe Non-beta-lactam Antibiotics Market Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Non-beta-lactam Antibiotics by Region (2019-2024)
8.2 Middle East & Africa Non-beta-lactam Antibiotics Market Size by Type (2019-2024)
8.3 Middle East & Africa Non-beta-lactam Antibiotics Market Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Non-beta-lactam Antibiotics Market Forecast
10.1 Global Non-beta-lactam Antibiotics Forecast by Region (2025-2030)
10.1.1 Global Non-beta-lactam Antibiotics Forecast by Region (2025-2030)
10.1.2 Americas Non-beta-lactam Antibiotics Forecast
10.1.3 APAC Non-beta-lactam Antibiotics Forecast
10.1.4 Europe Non-beta-lactam Antibiotics Forecast
10.1.5 Middle East & Africa Non-beta-lactam Antibiotics Forecast
10.2 Americas Non-beta-lactam Antibiotics Forecast by Country (2025-2030)
10.2.1 United States Market Non-beta-lactam Antibiotics Forecast
10.2.2 Canada Market Non-beta-lactam Antibiotics Forecast
10.2.3 Mexico Market Non-beta-lactam Antibiotics Forecast
10.2.4 Brazil Market Non-beta-lactam Antibiotics Forecast
10.3 APAC Non-beta-lactam Antibiotics Forecast by Region (2025-2030)
10.3.1 China Non-beta-lactam Antibiotics Market Forecast
10.3.2 Japan Market Non-beta-lactam Antibiotics Forecast
10.3.3 Korea Market Non-beta-lactam Antibiotics Forecast
10.3.4 Southeast Asia Market Non-beta-lactam Antibiotics Forecast
10.3.5 India Market Non-beta-lactam Antibiotics Forecast
10.3.6 Australia Market Non-beta-lactam Antibiotics Forecast
10.4 Europe Non-beta-lactam Antibiotics Forecast by Country (2025-2030)
10.4.1 Germany Market Non-beta-lactam Antibiotics Forecast
10.4.2 France Market Non-beta-lactam Antibiotics Forecast
10.4.3 UK Market Non-beta-lactam Antibiotics Forecast
10.4.4 Italy Market Non-beta-lactam Antibiotics Forecast
10.4.5 Russia Market Non-beta-lactam Antibiotics Forecast
10.5 Middle East & Africa Non-beta-lactam Antibiotics Forecast by Region (2025-2030)
10.5.1 Egypt Market Non-beta-lactam Antibiotics Forecast
10.5.2 South Africa Market Non-beta-lactam Antibiotics Forecast
10.5.3 Israel Market Non-beta-lactam Antibiotics Forecast
10.5.4 Turkey Market Non-beta-lactam Antibiotics Forecast
10.6 Global Non-beta-lactam Antibiotics Forecast by Type (2025-2030)
10.7 Global Non-beta-lactam Antibiotics Forecast by Application (2025-2030)
10.7.1 GCC Countries Market Non-beta-lactam Antibiotics Forecast
11 Key Players Analysis
11.1 Teva
11.1.1 Teva Company Information
11.1.2 Teva Non-beta-lactam Antibiotics Product Offered
11.1.3 Teva Non-beta-lactam Antibiotics Revenue, Gross Margin and Market Share (2019-2024)
11.1.4 Teva Main Business Overview
11.1.5 Teva Latest Developments
11.2 Novartis
11.2.1 Novartis Company Information
11.2.2 Novartis Non-beta-lactam Antibiotics Product Offered
11.2.3 Novartis Non-beta-lactam Antibiotics Revenue, Gross Margin and Market Share (2019-2024)
11.2.4 Novartis Main Business Overview
11.2.5 Novartis Latest Developments
11.3 Cipla
11.3.1 Cipla Company Information
11.3.2 Cipla Non-beta-lactam Antibiotics Product Offered
11.3.3 Cipla Non-beta-lactam Antibiotics Revenue, Gross Margin and Market Share (2019-2024)
11.3.4 Cipla Main Business Overview
11.3.5 Cipla Latest Developments
11.4 Pfizer
11.4.1 Pfizer Company Information
11.4.2 Pfizer Non-beta-lactam Antibiotics Product Offered
11.4.3 Pfizer Non-beta-lactam Antibiotics Revenue, Gross Margin and Market Share (2019-2024)
11.4.4 Pfizer Main Business Overview
11.4.5 Pfizer Latest Developments
11.5 Fresenius Kabi
11.5.1 Fresenius Kabi Company Information
11.5.2 Fresenius Kabi Non-beta-lactam Antibiotics Product Offered
11.5.3 Fresenius Kabi Non-beta-lactam Antibiotics Revenue, Gross Margin and Market Share (2019-2024)
11.5.4 Fresenius Kabi Main Business Overview
11.5.5 Fresenius Kabi Latest Developments
11.6 Sun Pharmaceutical
11.6.1 Sun Pharmaceutical Company Information
11.6.2 Sun Pharmaceutical Non-beta-lactam Antibiotics Product Offered
11.6.3 Sun Pharmaceutical Non-beta-lactam Antibiotics Revenue, Gross Margin and Market Share (2019-2024)
11.6.4 Sun Pharmaceutical Main Business Overview
11.6.5 Sun Pharmaceutical Latest Developments
11.7 Hikma Pharmaceuticals
11.7.1 Hikma Pharmaceuticals Company Information
11.7.2 Hikma Pharmaceuticals Non-beta-lactam Antibiotics Product Offered
11.7.3 Hikma Pharmaceuticals Non-beta-lactam Antibiotics Revenue, Gross Margin and Market Share (2019-2024)
11.7.4 Hikma Pharmaceuticals Main Business Overview
11.7.5 Hikma Pharmaceuticals Latest Developments
11.8 Lannett Company
11.8.1 Lannett Company Company Information
11.8.2 Lannett Company Non-beta-lactam Antibiotics Product Offered
11.8.3 Lannett Company Non-beta-lactam Antibiotics Revenue, Gross Margin and Market Share (2019-2024)
11.8.4 Lannett Company Main Business Overview
11.8.5 Lannett Company Latest Developments
11.9 FangYuan Pharmaceutical
11.9.1 FangYuan Pharmaceutical Company Information
11.9.2 FangYuan Pharmaceutical Non-beta-lactam Antibiotics Product Offered
11.9.3 FangYuan Pharmaceutical Non-beta-lactam Antibiotics Revenue, Gross Margin and Market Share (2019-2024)
11.9.4 FangYuan Pharmaceutical Main Business Overview
11.9.5 FangYuan Pharmaceutical Latest Developments
12 Research Findings and Conclusion

License Types: 

Single User License (PDF)

  • This license allows for use of a publication by one person.
  • This person may print out a single copy of the publication.
  • This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
  • This person cannot share the publication (or any information contained therein) with any other person or persons.
  • Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
  • Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

  • This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
  • These users may print out a single copy of the publication.
  • These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
  • These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
  • Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
  • Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

  • This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
  • Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
  • These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

Source URL:/lpi/global-non-beta-lactam-antibiotics-market-growth-status-and-outlook-2024-2030

Links
[1] /countries/global[2] /pharmaceutical-manufacturing[3] /healthcare[4] /pharma-healthcare